Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 12/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.46 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.46 |
| ▸ | PRKACA | P17612 | 1/20 | 0.46 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.46 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.46 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.46 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.46 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.46 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.46 |
| ▸ | CDC42BPB | Q9Y5S2 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PRKX | P51817 | 1/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1038440 | 0.80 | MAP2K1 (0.52) | MAP2K1ROCK1ROCK2PRKCDPRKACA | |
| SCHEMBL745351 | 0.80 | MAP2K1 (0.54) | MAP2K1ROCK1ROCK2PRKCDPRKACA | |
| SCHEMBL374997 | 0.78 | ROCK1 (0.56) | MAP2K1ROCK1ROCK2PRKCDPRKACA | |
| SCHEMBL4497910 | 0.77 | PARP1 (0.51) | APPMAOADYRK1APARP1 | |
| SCHEMBL17489612 | 0.76 | MAOA (0.53) | APPKDM4EMAPK1TDP1MAOA | |
| SCHEMBL1196073 | 0.75 | LTA4H (0.58) | APPMAPK1MAOADYRK1A | |
| SCHEMBL14861588 | 0.74 | CCNK (0.39) | APPMAPK1 | |
| SCHEMBL13423105 | 0.74 | MAP2K1 (0.64) | MAP2K1ROCK1ROCK2PRKCDPRKACA | |
| SCHEMBL9983791 | 0.73 | MAPK1 (0.66) | APPKDM4EMAPK1TDP1MAOA | |
| SCHEMBL30041284 | 0.73 | MAPK1 (0.66) | APPKDM4EMAPK1TDP1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458707-B1 | New Indol-2-one derivatives | ASTRAZENECA AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| US-7205314-B2 | Compounds for the treatment of dementia related diseases | ASTRAZENECA AB (SE) | 2007-04-17 | — | — | US | disclosed |
| US-20050065170-A1 | associated with the inhibition of glycogen synthase kinase-3, prevention and/or treatment of dementia related disease, Alzheimer's Disease etc.; example: 3-[6-(2-Methoxyethoxy)isoquinolin-1-yl]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | US | disclosed |
| EP-1458707-A2 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003053330-A2 | USE OF OXINDOLE DERIVATIVES IN THE TREATMENT OF DEMENTIA RELATED DISEASES, ALZHEIMER’S DISEASE AND CONDITIONS ASSOCIATED WITH GLYCOGEN SYNTHASE KINASE-3 | ASTRAZENECA AB (SE) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065170-A1 | associated with the inhibition of glycogen synthase kinase-3, prevention and/or treatment of dementia related disease, Alzheimer's Disease etc.; example: 3-[6-(2-Methoxyethoxy)isoquinolin-1-yl]-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile | GSK3A, GSK3B, PYGB | MAP2K1 919/4885ROCK1 148/4885ROCK2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.